ESMO 1538O Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study

Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study

Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study

Sublobar Resection vs Lobectomy for High-Risk Stage I Non–Small Cell Lung Carcinoma

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.

MA03.03 The Impact of AI-driven 3D Reconstruction on Pulmonary Surgery Planning (AIR-SURGE): A Multi-Center Multi-Reader Multi-Case Study (WCLC 2024)

MA03.07 Outcomes of Older Patients in CALGB 140503 (Alliance): Lobar vs Sublobar Resection for Peripheral Stage IA Non-Small Cell Lung Cancer [WCLC 2024]

Integrating IO in management of early lung-in both operative and inoperative setting.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671)

NEOTORCH Trial: Perioperative Toripalimab + Chemo in Resectable NSCLC – Phase 3 Results.

RATIONALE-315: Neoadjuvant Tislelizumab + Chemo in Resectable NSCLC – ESMO 2024 Results

AEGEAN Trial: Perioperative Durvalumab & ctDNA Clearance in Resectable NSCLC

NADIM Trial: 5-Year Outcomes of Perioperative Nivolumab + Chemo in Stage III NSCLC

ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data.

ADAURA Trial: MRD Analysis of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC – ASCO 2024

Combining Local & Systemic Therapy in NSCLC: Perioperative, Neoadjuvant & Adjuvant Strategies

Breakthrough in Stage III NSCLC: NRG-RTOG 1106 Adaptive Radiotherapy Trial Results (JCO 2024)

SEISMIC Trial Results: Endoscopic Mediastinal Staging to Guide Radiotherapy in NSCLC

NRG LU008 Trial: SBRT + Chemoradiation for Locally Advanced NSCLC | Phase III Results (JTO)

ESMO 2024: Beclomethasone Inhalation with Radiotherapy in LA-NSCLC | 1242MO Phase II Trial

LAURA Trial (NEJM/ASCO 2024): Osimertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC

POLESTAR Trial (WCLC 2024): Aumolertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC

PACIFIC-2 Final Results | Durvalumab + Chemoradiotherapy in Stage III NSCLC | ELCC 2024

Based on the Above Topics-common for CTRT -rt abstracts MO abstracts

HARMONi-2 Trial: Ivonescimab vs. Pembrolizumab in PD-L1+ NSCLC | Phase 3 Results

NVALT-30 Trial (ESMO 2024): Low vs. Standard Dose Pembrolizumab in Stage IV NSCLC |

Pembrolizumab + Chemo in PD-L1 NSCLC | 5-Year Survival Data (Pooled Analysis)

RELATIVITY-104 Trial: Nivolumab + Relatlimab + Chemo vs Nivolumab + Chemo in Stage IV NSCLC

GALAXIES Lung-201 (LBA52): Belrestotug + Dostarlimab in PD-L1 High NSCLC | Interim Phase II Data

TROPION-Lung01 Final OS: Datopotamab Deruxtecan vs Docetaxel in NSCLC |

Akkermansia muciniphila & Multi-Omic Profiling in Advanced NSCLC | ESMO 2024 Abstract 1172O

F. prausnitzii + PD-1 Inhibitors: Boosting Immunotherapy in NSCLC?

Treatment Strategies for Driver-Negative Metastatic NSCLC |

NRG-LU002: Trial for Limited Metastatic NSCLC | LCT + Maintenance vs Maintenance Therapy

OA05.03: Ablation + ICIs Boost Survival in Advanced NSCLC | Phase II Trial (WCLC 2024)

Thoracic RT Boosts Survival in EGFR-Mutant NSCLC with TKIs | Phase III Trial Results

OA05.05: ctDNA Predicts Molecular Oligometastatic NSCLC Before LCT | WCLC 2024 Highlights

NSCLC Breakthroughs at WCLC 2024: ctDNA, RT, ICIs, LCT Trials | Updates

hoosing the Right Therapy for Unresectable Stage III NSCLC | Treatment Options Explained

ESMO 1538O Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study

Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study

Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study

Sublobar Resection vs Lobectomy for High-Risk Stage I Non–Small Cell Lung Carcinoma

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.

MA03.03 The Impact of AI-driven 3D Reconstruction on Pulmonary Surgery Planning (AIR-SURGE): A Multi-Center Multi-Reader Multi-Case Study (WCLC 2024)

MA03.07 Outcomes of Older Patients in CALGB 140503 (Alliance): Lobar vs Sublobar Resection for Peripheral Stage IA Non-Small Cell Lung Cancer [WCLC 2024]

Integrating IO in management of early lung-in both operative and inoperative setting.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671)

NEOTORCH Trial: Perioperative Toripalimab + Chemo in Resectable NSCLC – Phase 3 Results.

RATIONALE-315: Neoadjuvant Tislelizumab + Chemo in Resectable NSCLC – ESMO 2024 Results

NADIM Trial: 5-Year Outcomes of Perioperative Nivolumab + Chemo in Stage III NSCLC

ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data.

ADAURA Trial: MRD Analysis of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC – ASCO 2024

Breakthrough in Stage III NSCLC: NRG-RTOG 1106 Adaptive Radiotherapy Trial Results (JCO 2024)

SEISMIC Trial Results: Endoscopic Mediastinal Staging to Guide Radiotherapy in NSCLC

NRG LU008 Trial: SBRT + Chemoradiation for Locally Advanced NSCLC | Phase III Results (JTO)

ESMO 2024: Beclomethasone Inhalation with Radiotherapy in LA-NSCLC | 1242MO Phase II Trial

LAURA Trial (NEJM/ASCO 2024): Osimertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC

POLESTAR Trial (WCLC 2024): Aumolertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC

PACIFIC-2 Final Results | Durvalumab + Chemoradiotherapy in Stage III NSCLC | ELCC 2024

Based on the Above Topics-common for CTRT -rt abstracts MO abstracts

HARMONi-2 Trial: Ivonescimab vs. Pembrolizumab in PD-L1+ NSCLC | Phase 3 Results

NVALT-30 Trial (ESMO 2024): Low vs. Standard Dose Pembrolizumab in Stage IV NSCLC |

Pembrolizumab + Chemo in PD-L1 NSCLC | 5-Year Survival Data (Pooled Analysis)

RELATIVITY-104 Trial: Nivolumab + Relatlimab + Chemo vs Nivolumab + Chemo in Stage IV NSCLC

GALAXIES Lung-201 (LBA52): Belrestotug + Dostarlimab in PD-L1 High NSCLC | Interim Phase II Data

TROPION-Lung01 Final OS: Datopotamab Deruxtecan vs Docetaxel in NSCLC |

Akkermansia muciniphila & Multi-Omic Profiling in Advanced NSCLC | ESMO 2024 Abstract 1172O

F. prausnitzii + PD-1 Inhibitors: Boosting Immunotherapy in NSCLC?

Treatment Strategies for Driver-Negative Metastatic NSCLC |

NRG-LU002: Trial for Limited Metastatic NSCLC | LCT + Maintenance vs Maintenance Therapy

OA05.03: Ablation + ICIs Boost Survival in Advanced NSCLC | Phase II Trial (WCLC 2024)

Thoracic RT Boosts Survival in EGFR-Mutant NSCLC with TKIs | Phase III Trial Results

OA05.05: ctDNA Predicts Molecular Oligometastatic NSCLC Before LCT | WCLC 2024 Highlights

NSCLC Breakthroughs at WCLC 2024: ctDNA, RT, ICIs, LCT Trials | Updates